LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...

Poxel to receive upfront payment of $35 million (approximately €28 million), potential future development and regulatory milestone payments and sales-based payments of up to $600 million ...

Poxel SA’s (ENXTPA:POXEL): Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with a primary focus on type II diabetes. The €150.20M market-cap company’s loss lessens since ...

LYON, France, November 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...

As a reminder, Tranche D PDR results from a contractual amendment to Tranche D of the IPF bond financing entered into in September 2024, as amended in September 2025 to finance the observation period, ...

*Net of R&D tax credit. Poxel generated revenue of €2.183 million in the first half of 2025, compared to €1.162 million during the same period in 2024, corresponding mainly to ¥345 million in ...

LYON, France, November 29, 2024--Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases ...

LYON, France, May 26, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with ...

Poxel has set out a new vision focused on midphase programs in rare metabolic diseases. The new strategy hits pause on plans to start a phase 2b nonalcoholic steatohepatitis (NASH) trial and makes no ...

Poxel generated consolidated revenue of €5 millions1 for the year ended 31 December 2025, compared with €6.6 million in the corresponding period in 2024, which included a milestone payment of ¥500 ...

OSAKA, Japan & LYON, France, August 07, 2024--Regulatory News: Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru ...

Bone Therapeutics (EBR:BOTHE) and Poxel (EPA:POXEL) have started life on European public markets with a bang. Both companies priced within their target ranges, sold out their overallotments and soared ...